Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

被引：0
作者：
Kan Yonemori
Kenji Tamura
Makoto Kodaira
Koshi Fujikawa
Tamotsu Sagawa
Taito Esaki
Tsuyoshi Shirakawa
Fumihiko Hirai
Yuki Yokoi
Toshio Kawata
Ben Hatano
Yasuo Takahashi
机构：
[1] National Cancer Center Hospital,Department of Breast and Medical Oncology
[2] National Hospital Organization Hokkaido Cancer Center,Department of Gastroenterology
[3] National Hospital Organization Kyushu Cancer Center,Department of Gastrointestinal and Medical Oncology
[4] National Hospital Organization Kyushu Cancer Center,Department of Thoracic Oncology
[5] AstraZeneca R and D,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Olaparib; Poly(ADP-ribose) polymerase inhibitors; Clinical trial, Phase I; Safety; Solid tumours;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：525 / 531
页数：6
相关论文
共 169 条
[41]  
Fong PC(undefined)undefined undefined undefined undefined-undefined
[42]  
Boss DS(undefined)undefined undefined undefined undefined-undefined
[43]  
Yap TA(undefined)undefined undefined undefined undefined-undefined
[44]  
Tutt A(undefined)undefined undefined undefined undefined-undefined
[45]  
Wu P(undefined)undefined undefined undefined undefined-undefined
[46]  
Mergui-Roelvink M(undefined)undefined undefined undefined undefined-undefined
[47]  
Mortimer P(undefined)undefined undefined undefined undefined-undefined
[48]  
Swaisland H(undefined)undefined undefined undefined undefined-undefined
[49]  
Lau A(undefined)undefined undefined undefined undefined-undefined
[50]  
O’Connor MJ(undefined)undefined undefined undefined undefined-undefined
12345678910